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OBJECTIVES The purpose of this study was to assess whether depressive symptoms are independently
associated with changes in heart failure (HF)-specific health status.
BACKGROUND Depression is common in patients with HF, but the impact of depressive symptoms on the
health status of these patients over time is unknown.
METHODS We conducted a multicenter prospective cohort study of outpatients with HF. Data from 460
patients who completed a baseline Medical Outcomes Study-Depression Questionnaire and
both a baseline and follow-up (6  2 weeks) Kansas City Cardiomyopathy Questionnaire
(KCCQ) were analyzed. The KCCQ measures HF-specific health status, including symp-
toms, physical and social function, and quality of life. Multivariable regression was used to
evaluate depressive symptoms as a predictor of change in KCCQ scores, adjusting for baseline
KCCQ scores and other patient variables. The primary outcome was change in KCCQ
summary scores (range 0 to 100; higher scores indicate better health status; 5 points is a
clinically meaningful change).
RESULTS Approximately 30% (139/460) of the patients had significant depressive symptoms at
baseline. Depressed patients had markedly lower baseline KCCQ summary scores ( 
19.6; p  0.001). After adjustment for potential confounders, depressed patients were at
risk for significant worsening of their HF symptoms, physical and social function, and quality
of life (average change in KCCQ summary score  7.1 points; p  0.001). Depressive
symptoms were the strongest predictor of decline in health status in the multivariable models.
CONCLUSIONS Depressive symptoms are a strong predictor of short-term worsening of HF-specific health
status. The recognition and treatment of depression may be an important component of HF
care. (J Am Coll Cardiol 2003;42:1811–7) © 2003 by the American College of Cardiology
Foundation
Nearly five million Americans have heart failure (HF) and
the prevalence continues to increase, leading some to
conclude that there is an “epidemic of heart failure” in the
U.S. (1,2). Patients with HF have impaired health status,
including severe symptom burden (e.g., dyspnea), marked
functional limitation, and diminished health-related quality
of life (3–5). Optimizing the health status of patients with
HF is an important goal of therapy, but little is known about
the specific factors influencing the health status of these
patients over time (6).
Depressive symptoms are common in patients with HF
(5,7,8) and may be an important determinant of health
status. However, the relationship between depression and
the health status of patients with HF independent of
traditional markers of disease severity and other patient
characteristics has not been studied. If depression is a major
predictor of HF-related health status, then improved rec-
ognition and treatment of depression may enhance out-
comes for these patients.
The objectives of this study were to: 1) determine the
frequency of depressive symptoms in a multicenter cohort of
outpatients with HF; 2) evaluate the cross-sectional associ-
ation between depressive symptoms and baseline HF-
specific health status; and 3) evaluate whether depressive
symptoms independently predict short-term changes in HF
symptoms, functional status, and quality of life.
METHODS
Study population. Patients were recruited through the
Cardiovascular Outcomes Research Consortium, a collabo-
rative of investigators from 14 North American centers
(Appendix). Outpatients with the diagnosis of HF in their
outpatient medical record or a hospitalization for decom-
pensated HF within three years were screened for partici-
pation. Patients with documented left ventricular systolic
dysfunction (left ventricular ejection fraction 0.40) and
who were 30 years of age were asked to participate and to
provide informed consent. There were no additional explicit
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exclusion criteria. Institutional review board approval was
obtained at each of the study sites.
After enrollment, patients underwent a complete history
and physical examination and a 6-min walk test (9). Study
participants also completed baseline surveys, including the
Kansas City Cardiomyopathy Questionnaire (KCCQ) and
the Medical Outcomes Study-Depression (MOS-D) ques-
tionnaire (10,11). After 6  2 weeks, patients returned to
complete a follow-up KCCQ along with repeat physical
examination, 6-min walk testing, and interim history. Of
546 patients enrolled, 460 (84.2%) completed both the
baseline and follow-up measures and form the cohort for
this study. Patients participating in follow-up were more
likely to be female (25.3% vs. 13.2%; p 0.03) and were less
likely to have a history of angina (23.6% vs. 39.7%; p 
0.01) than those who did not participate in follow-up.
There were no other significant differences in baseline
characteristics between participants and non-participants.
Variables. The primary independent, or predictor, variable
for this study was depressive symptoms as measured by the
baseline MOS-D. This instrument is a validated, eight-item
questionnaire for the screening of depressive symptoms
(11–13). A score of 0.06 on the MOS-D is approximately
85% sensitive and 75% specific for major depression, which
is comparable to other depression case finding instruments
(12,13). This scale was chosen over other depressive symp-
tom questionnaires because of minimal overlap in the
somatic symptom questions with heart failure symptoms.
Other independent variables included all of the demo-
graphic, cardiac, and comorbid variables listed in Table 1.
The primary dependent, or outcome, variable for this
study was disease-specific health status, as measured by the
KCCQ. The KCCQ is a 23-item, self-administered ques-
tionnaire with scales measuring the symptoms, physical
function, social function, self-efficacy, and quality of life of
patients with HF (10). These domains can be summarized
in a single summary score reflecting overall health status for
a given patient with HF. The scales are scored from 0 to 100
where higher scores represent fewer symptoms, better func-
tion, and/or better quality of life. The validity, reproduc-
ibility, and sensitivity of this measure to clinical changes
have previously been established (10). A change of 5 points
on KCCQ scale scores, either as a group mean or as an
intra-individual change, is considered clinically important.
The secondary outcome measure for this study was 6-min
walk distance. Hospitalization for HF was also evaluated
but was not an a priori outcome measure for this study.
Statistical analyses. Baseline characteristics of patients
with substantial depressive symptoms (MOS-D score
0.06) were compared with those patients without substan-
tial depressive symptoms (MOS-D score 0.06) using t
tests for continuous variables and chi-square tests for cate-
gorical variables. Then, t tests were used to compare
baseline KCCQ scores and 6-min walk distance between
patients with and without depressive symptoms. Multiple
linear regression was then used to define the independent,
cross-sectional association between baseline depressive
symptoms and baseline KCCQ summary scores, adjusting
for the demographic, cardiac, comorbid, and HF treatment
variables listed in Table 1. Depressive symptoms were
dichotomized as present (MOS-D score 0.06) versus
absent (MOS-D score 0.06) in the primary analyses. In
secondary analyses, MOS-D scores were analyzed as a
continuous variable (log-transformed), which did not sig-
nificantly alter the results.
To assess changes in health status, one-way analysis of
variance was used to compare changes in KCCQ scale
scores (stratified by baseline KCCQ scores) and changes in
6-min walk distance (stratified by baseline 6-min walk
quartiles) between patients with and without depressive
symptoms. Then, a series of multiple linear regression
models were developed to assess the independent relation-
ship between depressive symptoms and change from base-
line to follow-up in each of the outcome variables (change in
KCCQ scores, change in 6-min walk distance), adjusting
for the demographic, cardiac, comorbid, and heart failure
treatment variables listed in Table 1. Models were built by
applying forward stepwise selection to the variables in Table
1 (p  0.10 to enter the model; p  0.05 to stay in the final
model) and adding the depressive symptom variable to these
models as a final step. Unselected regression models were
also developed including all of the Table 1 variables as well
as depression to maximally control for confounding. Be-
cause the results of the selected and unselected models were
similar, only the parameter estimates from the unselected
models are presented. Finally, multiple logistic regression
was used to model a decline of 5 points in KCCQ
summary scores (i.e., a clinically important decline) versus
no change or improvement in score between baseline and
follow-up. Analyses of change in health status were strati-
fied by baseline KCCQ scores or 6-min walk quartiles to
account for baseline differences in health status between
depressed and non-depressed patients. This approach also
minimizes the chance that observed differences in health
status changes were confounded by regression to the mean
(14). Statistical analyses were performed using SAS version
8.0 (SAS Institute, Cary, North Carolina).
RESULTS
Baseline characteristics. Of the 460 patients in the study,
139 (30.2%) had substantial depressive symptoms at base-
line. Among patients classified as depressed, the median
Abbreviations and Acronyms
CI  confidence interval
HF  heart failure
KCCQ  Kansas City Cardiomyopathy Questionnaire
MOS-D  Medical Outcomes Study-Depression
Questionnaire
OR  odds ratio
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MOS-D score was 0.388 with a range of 0.060 to 0.930.
Among the patients classified as non-depressed, the median
MOS-D score was 0.002 with a range of 0.001 to 0.059.
Depressed patients were younger, more likely to smoke,
more likely to have a history of alcohol/substance abuse, and
more likely to have had previous depression requiring
treatment compared with non-depressed patients (Table 1).
However, the two groups of patients were similar with
regard to most baseline demographic, cardiac, and non-
cardiac factors. For example, in both groups the mean
ejection fraction was approximately 0.25, about one-half the
patients had an ischemic etiology of their HF, and about
one-third of the patients had diabetes.
There were no HF treatment differences between de-
pressed and non-depressed patients, and a high proportion
of patients were being treated with beta-blockers and
angiotensin-converting enzyme inhibitor or angiotensin re-
ceptor blocker agents in both groups. Among patients with
substantial depressive symptoms, 15.8% (22/139) were on
anti-depressant medical therapy.
Baseline health status. At baseline, depressed patients had
significantly lower KCCQ summary, symptom, physical
function, social function, and quality of life scores than
non-depressed patients (Table 2). In the multivariable
model adjusting for potential confounders, depressive symp-
toms were the strongest correlate of lower baseline KCCQ
summary scores (  19.6  standard error 2.2; p 
0.001).
Hospitalization. Hospitalization rates during the follow-up
period were 10.1% (14/139) for the depressed patients and
11.0% (36/327) for the non-depressed patients (p  0.8).
Changes in health status. Figures 1 to 3 demonstrate the
unadjusted relationship between baseline depressive symp-
toms and changes in KCCQ summary scores, symptom
scores, and 6-min walk distance, respectively. Similar rela-
tionships were found for the associations between baseline
Table 1. Baseline Comparison of Patients With and Without Substantial Depressive Symptoms
Variables
Depressed
(n  139)
Non-Depressed
(n  327) p Value
Demographic
Age (mean  SD), yrs 57.3  12.1 62.6  13.0  0.001
Gender (% male) 73.4 76.4 0.48
Race (% Caucasian) 70.7 66.9 0.56
Cardiac
Ischemic etiology of heart failure (%) 48.5 52.7 0.42
Left ventricular ejection fraction (mean  SD) 24.4  7.6 24.7  8.2 0.71
NYHA functional class (mean  SD) 2.6  0.8 2.3  0.7  0.01
BNP level (mean  SD) 319  381 400  389 0.11
Previous MI (%) 41.7 39.1 0.60
Previous PCI (%) 13.0 13.8 0.81
Previous CABG surgery (%) 23.0 29.0 0.18
Previous angina (%) 28.8 22.3 0.14
Pacemaker or ICD (%) 23.0 26.0 0.50
Atrial fibrillation (%) 23.7 34.2 0.03
Non-cardiac
Hypertension (%) 57.6 54.7 0.58
Hyperlipidemia (%) 51.8 45.9 0.24
Current smoker (%) 23.0 13.4 0.01
Alcohol or substance abuse (%) 25.9 16.8 0.02
Previous depression requiring treatment (%) 20.1 8.9  0.001
Diabetes mellitus (%) 33.1 32.4 0.89
COPD (%) 18.0 19.9 0.64
Stroke or TIA (%) 14.4 9.8 0.15
PVD (%) 10.1 6.4 0.17
Renal failure (%) 6.5 4.9 0.49
Treatment
Aspirin (%) 55.4 58.1 0.59
Beta-blocker (%) 78.4 74.0 0.31
ACE-I or ARB (%) 91.4 93.3 0.46
Diuretic (%) 79.9 82.3 0.54
Spironolactone (%) 35.3 37.0 0.72
Digoxin (%) 63.3 64.2 0.85
Anti-depressant (%) 15.8 8.3 0.01
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BNP  B-type natriuretic peptide;
CABG  coronary artery bypass graft; COPD  chronic obstructive pulmonary disease; ICD  implantable cardioverter
defibrillator; MI  myocardial infarction; NYHA  New York Heart Association; PCI  percutaneous coronary intervention;
PVD  peripheral vascular disease; TIA  transient ischemic attack.
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depressive symptoms and changes in KCCQ physical lim-
itation, social limitation, and quality of life scales (not
shown). In each case, depressed patients with fair to good
baseline health status (i.e., upper two quartiles) were much
more likely to suffer significant declines in health status over
the follow-up period compared with non-depressed patients
(p  0.001). Furthermore, depressed patients with poor
baseline health status (i.e., lower two quartiles) had signif-
icantly less improvement over the follow-up period com-
pared with non-depressed patients.
In multiple linear regression analyses, depressive symp-
toms were significantly associated with declines in HF-
related health status (Table 3). Depressed patients were at
risk for statistically and clinically significant declines (i.e.,
5 points) on the KCCQ summary, symptom, physical
function, social function, and quality of life scales. Depres-
sive symptoms were also independently associated with
declines in 6-min walk distance. In the multivariable models
of change in KCCQ summary scores, symptom scores,
social function, and quality of life, depressive symptoms had
the largest magnitude of association with the outcome.
In multiple logistic regression analysis, depressive symp-
toms were predictive of clinically significant (5 points)
declines in KCCQ summary scores (odds ratio [OR] 2.5,
95% confidence interval [CI] 1.5 to 4.2). Other significant
predictors of decline in KCCQ scores included a history of
alcohol/substance abuse (OR 2.4, 95% CI 1.4 to 4.3),
diabetes (OR 1.7, 95% CI 1.1 to 2.7), older age (OR 1.2,
95% CI 1.0 to 1.5, per 10-year increment), and baseline
KCCQ scores (OR 1.2, 95% CI 1.1 to 1.3, per 10-point
increment).
DISCUSSION
The primary goal of this study was to evaluate the strength
of association between depressive symptoms and six-week
changes in HF-related health status. The study population
was composed of outpatients with HF, and there were no
differences in HF treatment between depressed and non-
depressed patients at baseline. Nevertheless, depressive
symptoms were common in this population, and depressed
patients had markedly worse baseline health status than
non-depressed patients. After adjusting for baseline health
status and over 20 patient variables, depressed patients were
at risk for significant worsening of their HF symptoms,
physical and social functional status, and quality of life. In
fact, depressive symptoms were the strongest predictor of
decline in health status in the multivariable models. There-
fore, HF outpatients with depression are not only at risk for
worse baseline health status, but also for short-term declines
in their HF symptoms, function, and quality of life.
To our knowledge, this is the first study to demonstrate
the impact of depressive symptoms on HF-specific health
status over time. The results of this study expand the scope
Figure 1. The unadjusted association between depressive symptoms and
change in heart failure-specific health status as measured by the Kansas
City Cardiomyopathy Questionnaire (KCCQ): change on the KCCQ
summary score between baseline and the 6 2 week follow-up assessment.
White bars  non-depressed patients; shaded bars  depressed patients.
p  0.001 for main effect of depression.
Figure 2. The unadjusted association between depressive symptoms and
change in heart failure symptoms as measured by the Kansas City
Cardiomyopathy Questionnaire (KCCQ): change on the KCCQ symptom
score between baseline and the 6  2 week follow-up assessment. White
bars  non-depressed patients; shaded bars  depressed patients. p 
0.001 for main effect of depression.
Table 2. Baseline Health Status of Patients With and Without Substantial Depressive
Symptoms
Health Status Measure
Depressed
(n  139)
Non-Depressed
(n  327) p Value
KCCQ summary score 47.7 67.3  0.001
KCCQ symptom score 57.4 73.6  0.001
KCCQ physical function score 53.6 66.4  0.001
KCCQ social function score 40.5 64.1  0.001
KCCQ quality of life score 39.1 64.9  0.001
Six-minute walk distance (m) 285.5 304.7 0.12
KCCQ  Kansas City Cardiomyopathy Questionnaire.
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of previous studies that demonstrated an independent asso-
ciation between depressive symptoms and adverse outcomes
in patients with HF, including increased mortality, higher
rates of hospitalization, and declines in activities in daily
living (5,15,16). Although this study did not find a signif-
icant difference in hospitalization rates between depressed
and non-depressed patients, it was not powered for this
outcome. Nonetheless, we were able to demonstrate mean-
ingful differences in health status outcomes between de-
pressed and non-depressed patients. In fact, a focus on
mortality and hospitalization would have obscured the
burden of depressive symptoms on these HF patients.
Furthermore, a focus on health status outcomes is con-
sistent with the Institute of Medicine’s promotion of
patient-centered care as one of the six key strategies to
improving the quality of care in the U.S. (17). Factors such
as the aging population, increasing prevalence of HF, and
evidence that many older persons prefer quality of life to
quantity of life further underscore the importance of eval-
uating patient-centered outcomes in this population
(1,2,18). The results of this study suggest that patient-
centered outcomes for HF outpatients may be improved
through better recognition and treatment of depression.
To date, efforts to improve the quality of care for patients
with HF have focused on processes of care specific to HF
(e.g., angiotensin-converting enzyme inhibitors for left ven-
tricular systolic dysfunction) (19), largely ignoring the im-
pact of prevalent comorbid conditions. In our study, nearly
one-third of the patients in this study had significant
depressive symptoms, and yet, less than one-fifth of the
depressed patients were receiving anti-depressant medica-
tion. These findings are consistent with previous studies
reporting that depression is common in HF populations
(5,7,8) and that the majority of depressed patients with HF
are not being treated for depression (20). Because depres-
sion is common, is associated with adverse outcomes, and
appears to be under-recognized and under-treated, it de-
serves increased attention from clinicians and investigators.
Previous studies in post-myocardial infarction popula-
tions have not shown that depression screening and treat-
ment reduces mortality (21,22). However, these trials did
show that depression detection and treatment strategies are
effective in alleviating depression and demonstrated that
there are safe and effective treatments available for depres-
sion in patients with cardiovascular disease, including selec-
tive serotonin reuptake inhibitors. Unfortunately, these
studies did not focus on health status outcomes. Further-
more, the efficacy of depression screening and treatment has
not been evaluated in HF populations. One may anticipate
more transient, or situational, depression in post-myocardial
infarction patients compared with HF patients, who are
faced with a chronic condition characterized by exacerba-
tions and clinical decline and, therefore, may remain de-
pressed for prolonged periods of time (20,23). Future
studies are warranted to investigate the impact of improved
depression management in patients with HF on a broad
range of outcomes. In the meantime, however, there are
inherent benefits to the recognition and treatment of de-
pression.
An important barrier to the incorporation of depression
management into the care of patients with HF may be that
non-psychiatrist clinicians do not feel capable of identifying
and treating depression. However, it has been shown that
significant depressive symptoms can be identified in primary
care settings using two simple screening questions and that
the vast majority of patients with depressive symptoms can
be treated effectively without psychiatric referral (12,24).
The recognition and management of depression may be
enhanced through the use of multidisciplinary teams or
disease management programs that have been successfully
applied to other aspects of HF care (25–28).
The reasons for the high prevalence of depressive symp-
toms and the strong association between depressive symp-
toms and adverse outcomes in patients with HF are un-
known. Depression may be a risk factor for the development
of HF (29,30). Conversely, chronic illnesses such as HF
may precipitate depression. In either case, there are both
behavioral and pathophysiologic mechanisms by which
depressive symptoms may lead to adverse outcomes in
patients with HF. For example, depressed patients are at
Figure 3. The unadjusted association between depressive symptoms and
change in functional status as measured by the 6-min walk test: change in
6-min walk distance (m) between baseline and the 6  2 week follow-up
assessment. White bars  non-depressed patients; shaded bars  de-
pressed patients. p  0.001 for main effect of depression.
Table 3. Average Change in Health Status of Patients With
Depressive Symptoms, Adjusted for Baseline Health Status and
Clinical Characteristics*
Health Status Measure
Average Change
in Score
(Standard Error) p Value
KCCQ summary score 7.1 (1.5)  0.001
KCCQ symptom score 8.1 (1.7)  0.001
KCCQ physical function score 5.7 (1.9) 0.002
KCCQ social function score 9.8 (2.4)  0.001
KCCQ quality of life score 11.0 (2.0)  0.001
Six-minute walk distance (m) 20.0 (9.0) 0.03
*Change from baseline to 6  2 week follow-up assessment. Adjusted for the
demographic, cardiac, non-cardiac, and treatment variables listed in Table 1.
KCCQ  Kansas City Cardiomyopathy Questionnaire.
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risk for medical noncompliance, and there is evidence that
depression is associated with high sympathetic tone, hyper-
cortisolemia, increased platelet aggregability, and elevated
inflammatory markers (31–34).
Several potential limitations of this study should be
addressed. First, this study enrolled a convenience sample of
outpatients with HF and, therefore, may have limited
generalizability. However, one may expect fewer depressed
patients to participate in such a study, and therefore our
sample may underestimate the true prevalence of depressive
symptoms in outpatients with HF. Second, the MOS-D
measures depressive symptoms and is not a diagnostic tool
for major depressive disorder as defined by the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edi-
tion. However, the diagnostic accuracy of the MOS-D for
major depression is relatively high and is comparable to
other depression screening instruments (12,13). Further-
more, multiple studies in cardiac populations have demon-
strated the prognostic importance of depressive symptoms,
irrespective of a diagnosis of major depression (34–36).
Third, we only assessed patients at two points in time within
a relatively short interval. However, we were able to dem-
onstrate a strong association between depressive symptoms
and declines in health status even within this time period.
Future studies should examine the relationship between
depressive symptoms and longer-term outcomes in outpa-
tients with HF.
In conclusion, depressive symptoms are common in
patients with HF, are associated with markedly worse
baseline health status, and are a strong predictor of wors-
ening of HF symptoms, functional status, and quality of life
over time. While additional studies should explicitly evalu-
ate whether the improved recognition and treatment of
depression will improve outcomes, clinicians should be
aware of the strong link between depressive symptoms and
adverse health status outcomes in patients with HF.
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APPENDIX
For a detailed list of the sites and principal investigators for
this study, please see the November 19, 2003, issue of JACC
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